Additionally, GAS5 suppresses the oncogenic activity of enhancer of zeste homolog 2 (EZH2), an epigenetic modifier overexpressed in cancers like melanoma [132] and bladder cancer [18], by recruiting the transcriptional repressor E2F4 to the EZH2 promoter, thereby downregulating EZH2 expression and restoring tumor suppressor genes such as cyclin dependent kinase inhibitor 1C (CDKN1C) [133]. Here, GAS5 is linked to urinary bladder carcinoma.